Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia
Author:
Funder
Indian Council of Medical Research
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00228-022-03345-8.pdf
Reference32 articles.
1. Hu Y, Li Q, Hou M et al (2021) Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the Global Burden of Disease Study 2019. JCO Glob Oncol 1429–1441. https://doi.org/10.1200/GO.21.00194
2. Peng B, Hayes M, Resta D et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. JCO 22:935–942. https://doi.org/10.1200/JCO.2004.03.050
3. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037. https://doi.org/10.1056/NEJM200104053441401
4. Bhutani N (2020) Chronic myeloid leukemia in India: a review. https://doi.org/10.5281/ZENODO.3926873
5. Adeagbo BA, Olugbade TA, Durosinmi MA et al (2017) Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance. J Clin Pharmacol 57:1554–1563. https://doi.org/10.1002/jcph.953
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients;Pharmaceutics;2024-06-19
2. Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol;Expert Opinion on Drug Metabolism & Toxicology;2024-06-02
3. Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients;Cancer Chemotherapy and Pharmacology;2024-03-05
4. Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation;Pharmacogenomics;2023-12
5. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation;Cancer Chemotherapy and Pharmacology;2023-08-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3